Register Login

Syndax Pharmaceuticals Inc (SNDX)

(90% Positive) Syndax Pharmaceuticals Inc (SNDX) Announces Enrollment Update for acceleration Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:51 p.m.

    📋 Syndax Pharmaceuticals Inc (SNDX) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 16:36:11

    Event Type: Clinical Trial Update

    Event Details:

    Syndax Pharmaceuticals Inc (SNDX) Announces Clinical Trial Update Syndax Pharmaceuticals Inc (SNDX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: acceleration, increase
    • Collaboration: AML
    • Updated Timeline: year 2025, fourth quarter and full year 2025

    🔬 Clinical Development Pipeline (Syndax Pharmaceuticals Inc):

    Product Type Development Stage Therapeutic Area Source
    Placebo OTHER Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    Azacitidine DRUG Phase PHASE1 Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE1 Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    Chemotherapy DRUG Phase PHASE1 Colorectal Cancer ClinicalTrials.gov
    Revumenib DRUG Phase PHASE1 Colorectal Cancer ClinicalTrials.gov
    Methotrexate DRUG Phase PHASE1 Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    Cytarabine DRUG Phase PHASE1 Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    intrathecal (IT) chemotherapy DRUG Phase PHASE1 Refractory Acute Myeloid Leukemia ClinicalTrials.gov
    Axatilimab DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    Intensive Chemotherapy Regimen DRUG Phase PHASE3 Acute Myeloid Leukemias ClinicalTrials.gov
    HiDAC DRUG Phase PHASE1 Acute Myeloid Leukemias ClinicalTrials.gov
    Chemotherapy Regimen DRUG Phase PHASE1 Acute Myeloid Leukemias ClinicalTrials.gov
    SNDX-5613 DRUG Phase PHASE1 Acute Myeloid Leukemias ClinicalTrials.gov
    cobicistat DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    ASTX727 DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Procedure/Surgery PROCEDURE Phase PHASE2 Bladder Cancer ClinicalTrials.gov
    Entinostat DRUG Phase PHASE2 Bladder Cancer ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE2 Bladder Cancer ClinicalTrials.gov
    Fulvestrant DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    Midazolam DRUG Phase PHASE1 Drug Interaction ClinicalTrials.gov
    FOLFOX regimen DRUG Phase PHASE1 Pancreas Cancer ClinicalTrials.gov
    exemestane DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Erlotinib DRUG Phase PHASE1 Lung Cancer ClinicalTrials.gov
    therapeutic conventional surgery PROCEDURE Phase PHASE2 Estrogen Receptor-negative Breast Cancer ClinicalTrials.gov
    diagnostic laboratory biomarker analysis OTHER Phase PHASE2 Estrogen Receptor-negative Breast Cancer ClinicalTrials.gov
    anastrozole DRUG Phase PHASE2 Estrogen Receptor-negative Breast Cancer ClinicalTrials.gov
    Aromatase Inhibitor (AI) Therapy DRUG Phase PHASE2 ER+ Breast Cancer ClinicalTrials.gov
    SNDX-275 DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    SNDX-6352 DRUG Phase PHASE2 Coronavirus ClinicalTrials.gov
    Interleukin-2 DRUG Phase PHASE2 Renal Cell Carcinoma ClinicalTrials.gov
    Capecitabine DRUG Phase PHASE1 Metastatic Breast Cancer ClinicalTrials.gov
    Durvalumab DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    avelumab DRUG Phase PHASE1 Epithelial Ovarian Cancer ClinicalTrials.gov
    Chemotherapy Regimen 2 DRUG Phase PHASE1 Relapsed/Refractory Leukemias ClinicalTrials.gov
    Chemotherapy Regimen 1 DRUG Phase PHASE1 Relapsed/Refractory Leukemias ClinicalTrials.gov
    Daunorubicin DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Midostaurin DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Bevacizumab DRUG Phase PHASE1 Metastatic Cancer ClinicalTrials.gov
    Atezolizumab DRUG Phase PHASE1 Metastatic Cancer ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE2 Metastatic Cholangiocarcinoma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Syndax Pharmaceuticals Inc
    • Ticker Symbol: SNDX

Search

News categories